Balancing collective responsibility, individual opportunities and risks: a qualitative study on how police officers reason around volunteering in an HIV vaccine trial in Dar es Salaam, Tanzania

Tarimo, Edith A. M.; Thorson, Anna; Kohi, Thecla W.; Mwami, Joachim; Bakari, Muhammad; Sandström, Eric; Kulane, Asli
January 2010
BMC Public Health;2010, Vol. 10 Issue 1, p292
Academic Journal
Background: Results from HIV vaccine trials on potential volunteers will contribute to global efforts to develop an HIV vaccine. The purpose of this study among police officers in Dar es Salaam, Tanzania, was to explore the underlying reasons that induce people to enrol in an HIV vaccine trial. Methods: We conducted discussions with eight focus groups, containing a total of 66 police officers. The information collected was analyzed using interpretive description. Results: The results showed that participants were motivated to participate in the trial by altruism, and that the participants experienced some concerns about their participation. They stated that altruism in the fight against HIV infection was the main reason for enrolling in the trial. However, young participants were seriously concerned about a possible loss of close relationships if they enrolled in the HIV vaccine trial. Both men and women feared the effect of the trial on their reproductive biology, and they feared interference with pregnancy norms. They were unsure about risks such as the risks of acquiring HIV infection and of suffering physical harm, and they were unsure of the intentions of the researchers conducting the trial. Further, enrolling in the trial required medical examination, and this led some participants to fear that unknown diseases would be revealed. Other participants, however, saw an opportunity to obtain free health services. Conclusions: We have shown that specific fears are important concerns when recruiting volunteers to an HIV vaccine trial. More knowledge is needed to determine participants' views and to ensure that they understand the conduct of the trial and the reasons it is being carried out.


Related Articles

  • Revised BCG vaccination guidelines for infants at risk for HIV infection.  // Weekly Epidemiological Record;5/25/2007, Vol. 82 Issue 21, p193 

    The article discusses the revised guidelines for bacille Calmette-Guérin vaccination in human immunodeficiency virus (HIV) infected infants. To implement the recommendations from the Global Advisory Committee on Vaccine Safety, the factors in assessing the risk for HIV infection should be...

  • Population-Based Surveillance for Invasive Pneumococcal Disease in Homeless Adults in Toronto. Plevneshi, Agron; Svoboda, Tomislav; Armstrong, Irene; Tyrrell, Gregory J.; Miranda, Anna; Green, Karen; Low, Donald; McGeer, Allison // PLoS ONE;2009, Vol. 4 Issue 9, p1 

    Background: Identification of high-risk populations for serious infection due to S. pneumoniae will permit appropriately targeted prevention programs. Methods: We conducted prospective, population-based surveillance for invasive pneumococcal disease and laboratory confirmed pneumococcal...

  • When the vaccine causes disease. Mandavilli, Apoorva // Nature Medicine;Mar2007, Vol. 13 Issue 3, p274 

    The article reports on the adverse effects of Bacille Calmette-Guerin (BCG) vaccination among infants infected with HIV. For decades, the World Health Organization (WHO) has recommended that every newborn at risk of tuberculosis (TB) should be protected with a single-dose of the BCG vaccine as...

  • Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward. Lo, Ying-Ru; Chu, Carissa; Ananworanich, Jintanat; Excler, Jean-Louis; Tucker, Joseph D. // AIDS Patient Care & STDs;Jul2015, Vol. 29 Issue 7, p389 

    Clinical and basic science advances have raised considerable hope for achieving an HIV cure by accelerating research. This research is dominated primarily by issues about the nature and design of current and future clinical trials. Stakeholder engagement for HIV cure remains in its early stages....

  • From HIV to Tuberculosis and Back Again: A Tale of Activism in 2 Pandemics. Harrington, Mark // Clinical Infectious Diseases;May2010 Supplement 3, Vol. 50, pS260 

    Tuberculosis (TB) and human immunodeficiency virus (HIV) infections are the deadliest chronic infections globally. Although each is deadly alone, they are deadlier together, with TB causing one-quarter of AIDS-related deaths and HIV infecting at least 15% of patients with TB worldwide....

  • HIV prevention trials in danger of grinding to a standstill. Check, Erika // Nature Reviews Drug Discovery;Oct2006, Vol. 5 Issue 10, p806 

    Researchers unable to get meaningful data on effectiveness of new treatments

  • Phylodynamics of HIV-1 from a Phase III AIDS Vaccine Trial in Bangkok, Thailand. Pérez-Losada, Marcos; Jobes, David V.; Sinangil, Faruk; Crandall, Keith A.; Arenas, Miguel; Posada, David; Berman, Phillip W. // PLoS ONE;2011, Vol. 6 Issue 3, p1 

    Background: In 2003, a phase III placebo-controlled trial (VAX003) was completed in Bangkok, Thailand. Of the 2,546 individuals enrolled in the trial based on high risk for infection through injection drug use (IDU), we obtained clinical samples and HIV-1 sequence data (envelope glycoprotein...

  • The quest for the AIDS vaccine. Tonks, Alison // BMJ: British Medical Journal (International Edition);6/30/2007, Vol. 334 Issue 7608, p1346 

    The article focuses on problems researchers are facing in 2007 when attempting to discover a vaccine for AIDS. Arguments are presented which suggest that finding vaccines for the disease are difficult because HIV is one of the most complex viruses ever identified and is extremely good at evading...

  • Evaluating the impact of the HIV pandemic on measles control and elimination. Helfand, Rita F.; Moss, William J.; Harpaz, Rafael; Scott, Susana; Cutts, Felicity // Bulletin of the World Health Organization;May2005, Vol. 83 Issue 5, p329 

    Objective To estimate the impact of the HIV pandemic on vaccine-acquired population immunity to measles virus because high levels of population immunity are required to eliminate transmission of measles virus in large geographical areas, and HIV infection can reduce the efficacy of measles...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics